Thursday, 15 October 2026European Markets

BENETEAU Stock Went Up By Over 11% So Far On Thursday

Loading stream...

(vianews) - shares of beneteau (cac 40: ben.pa) rose by a staggering 11.86% to €16.98 at 11:53 est on thursday, following the last session's downward trend. cac 40 is rising 0.83% to €7,422.24, after two consecutive sessions in a row of losses. this seems, as yet, a somewhat positive trend trading session today.

beneteau's last close was €15.18, 12.96% below its 52-week high of €17.44.

about beneteau

bénéteau s.a. designs, manufactures, and sells boats and leisure homes in france and internationally. it provides boats under the beneteau, jeanneau, lagoon, prestige, monte carlo yachts, four winns, glastron, scarab, wellcraft, excess, and delphia brand names; and leisure homes under the irm, o'hara, and coco sweet brand names. the company also offers bandofbaots.com, a community services platform for purchase and sale of new or used boats; lease purchase, credit, and insurance services through sgb finance; and inventory and retail finance solutions. bénéteau s.a. was founded in 1884 and is headquartered in saint gilles croix de vie, france.

earnings per share

as for profitability, beneteau has a trailing twelve months eps of €1.21.

pe ratio

beneteau has a trailing twelve months price to earnings ratio of 14.03. meaning, the purchaser of the share is investing €14.03 for every euro of annual earnings.

volatility

beneteau's last week, last month's, and last quarter's current intraday variation average was 1.52%, 0.07%, and 1.47%.

beneteau's highest amplitude of average volatility was 1.79% (last week), 1.02% (last month), and 1.47% (last quarter).

moving average

beneteau's value is above its 50-day moving average of €15.59 and way above its 200-day moving average of €13.11.

sales growth

beneteau's sales growth for the current quarter is 11.1%.

more news about beneteau (ben.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com